

- Feuerriegel S, Köser CU, Baù D et al. (2011). Impact of Fgd1 and ddn diversity in *Mycobacterium tuberculosis* complex on *in vitro* susceptibility to PA-824. *Antimicrob Agents Chemother* **55**: 5718.
- Ginsberg AM, Laurenzi MW, Rouse DJ et al. (2009a). Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. *Antimicrob Agents Chemother* **53**: 3726.
- Ginsberg AM, Laurenzi MW, Rouse DJ et al. (2009b). Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. *Antimicrob Agents Chemother* **53**: 3720.
- Gler MT, Skripconoka V, Sanchez-Garavito E et al. (2012). Delamanid for multidrug-resistant pulmonary tuberculosis. *N Engl J Med* **366**: 2151.
- Global Alliance for TB Drug Development (2008). OPC-67683, PA-824. *Tuberculosis (Edinb)* **88**: 132.
- Gupta R, Geiter LJ, Hafkin J et al. (2015a). Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* **19**: 1261.
- Gupta R, Geiter LJ, Wells CD et al. (2015b). Delamanid for extensively drug-resistant tuberculosis. *N Engl J Med* **373**: 291.
- Haraus E, Cox H, Rich M et al. (2015). QTc prolongation and treatment of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* **19**: 385.
- Haver HL, Chua A, Ghode P et al. (2015). Mutations in the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous *in vitro* selected PA-824 mutants of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* **59**: 5316.
- Hurdle JG, Lee RB, Budha NR et al. (2008). A microbiological assessment of novel nitrofuranyl amides as anti-tuberculosis agents. *J Antimicrob Chemother* **62**: 1037.
- Keller PM, Hömke R, Ritter C et al. (2015). Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in *Mycobacterium tuberculosis* using the MGIT 960 system equipped with TB eXiST. *Antimicrob Agents Chemother* **59**: 4352.
- Lachatre M, Rioux C, Le Du D et al. (2016). Bedaquiline plus delamanid for XDR tuberculosis. *Lancet Infect Dis* **16**: 294.
- Laurenzi M, Ginsberg A, Spigelman M (2007). Challenges associated with current and future TB treatment. *Infect Disord Drug Targets* **7**: 105.
- Manjunatha U, Boshoff HI, Barry CE (2009). The mechanism of action of PA-824: Novel insights from transcriptional profiling. *Commun Integr Biol* **2**: 215.
- Manjunatha UH, Boshoff H, Dowd CS et al. (2006a). Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* **103**: 431.
- Manjunatha UH, Lahiri R, Randhawa B et al. (2006b). *Mycobacterium leprae* is naturally resistant to PA-824. *Antimicrob Agents Chemother* **50**: 3350.
- Matsumoto M, Hashizume H, Tomishige T et al. (2006). OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis *in vitro* and in mice. *PLoS Med* **3**: e466.
- Mukherjee T, Boshoff H (2011). Nitroimidazoles for the treatment of TB: past, present and future. *Future Med Chem* **3**: 1427.
- Purwantini E, Mukhopadhyay B (2013). Rv0132c of *Mycobacterium tuberculosis* encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase. *PLoS One* **8**: e81985.
- Sashara K, Shimokawa Y, Hirao Y et al. (2015). Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism *in vivo*. *Drug Metab Dispos* **43**: 1267.
- Shimokawa Y, Sasahara K, Yoda N et al. (2014). Delamanid does not inhibit or induce cytochrome p450 enzymes *in vitro*. *Biol Pharm Bull* **37**: 1727.
- Singh R, Manjunatha U, Boshoff HIM et al. (2008). PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release. *Science* **322**: 1392.
- Skripconoka V, Danilovits M, Pehme L et al. (2013). Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. *Eur Respir J* **41**: 1393.
- Stinson K, Kurepina N, Venter A et al. (2016). MIC of delamanid (OPC-67683) against *Mycobacterium tuberculosis* clinical isolates and proposed critical concentration. *Antimicrob Agents Chemother* **60**: 3316.
- Stover CK, Warrenner P, VanDevanter DR et al. (2000). A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* **405**: 962.
- Tasneen R, Li S-Y, Peloquin CA et al. (2011). Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. *Antimicrob Agents Chemother* **55**: 5485.
- Tasneen R, Betoudji F, Tyagi S et al. (2015). Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. *Antimicrob Agents Chemother* **60**: 270.
- Wang L, Ma Y, Duan H et al. (2015). Pharmacokinetics and tissue distribution study of PA-824 in rats by LC-MS/MS. *J Chromatog B* **1006**: 194.
- Winter H, Egizi E, Erundu N et al. (2013a). Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects. *Antimicrob Agents Chemother* **57**: 3699.
- Winter H, Ginsberg A, Egizi E et al. (2013b). Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. *Antimicrob Agents Chemother* **57**: 5516.
- World Health Organization (2014). The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. ncbi.nlm.nih.gov/books/NBK299541. Accessed 30 October 2015.
- Zumla A, Nahid P, Cole ST (2013). Advances in the development of new tuberculosis drugs and treatment regimens. *Nat Rev Drug Discov* **12**: 388.